Header Logo

Connection

Naoko Takebe to Neoplasms

Back to Details
This is a "connection" page, showing publications Naoko Takebe has written about Neoplasms.
Naoko Takebe
Connection Strength
7.707
Neoplasms
  1. Blood-based multi-cancer detection: A state-of-the-art update. Curr Probl Cancer. 2024 02; 48:101059.
    View in: PubMed
    Score: 0.478
  2. Safety, Antitumor Activity, and Biomarker Analysis in a Phase I Trial of the Once-daily Wee1 Inhibitor Adavosertib (AZD1775) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2021 07 15; 27(14):3834-3844.
    View in: PubMed
    Score: 0.395
  3. Targeting signalling pathways and the immune microenvironment of cancer stem cells - a clinical update. Nat Rev Clin Oncol. 2020 04; 17(4):204-232.
    View in: PubMed
    Score: 0.360
  4. A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. Br J Clin Pharmacol. 2019 11; 85(11):2499-2511.
    View in: PubMed
    Score: 0.354
  5. Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. Cancer J. 2019 Jul/Aug; 25(4):296-299.
    View in: PubMed
    Score: 0.349
  6. A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. Clin Pharmacol Ther. 2019 10; 106(4):803-809.
    View in: PubMed
    Score: 0.345
  7. Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose-finding trials. Cancer Sci. 2018 Jan; 109(1):207-214.
    View in: PubMed
    Score: 0.313
  8. Considerations of developing an NGS assay for clinical applications in precision oncology: The NCI-MATCH NGS assay experience. Curr Probl Cancer. 2017 May - Jun; 41(3):201-211.
    View in: PubMed
    Score: 0.301
  9. Drug induced interstitial lung disease in oncology phase?I trials. Cancer Sci. 2016 Dec; 107(12):1830-1836.
    View in: PubMed
    Score: 0.292
  10. Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration. Semin Radiat Oncol. 2016 10; 26(4):271-80.
    View in: PubMed
    Score: 0.283
  11. Perspectives on research activity in the USA on Cancer Precision Medicine. Jpn J Clin Oncol. 2016 Feb; 46(2):106-10.
    View in: PubMed
    Score: 0.271
  12. Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development. Jpn J Clin Oncol. 2015 Nov; 45(11):1001-6.
    View in: PubMed
    Score: 0.269
  13. Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update. Nat Rev Clin Oncol. 2015 Aug; 12(8):445-64.
    View in: PubMed
    Score: 0.260
  14. Biomarkers: exceptional responders-discovering predictive biomarkers. Nat Rev Clin Oncol. 2015 Mar; 12(3):132-4.
    View in: PubMed
    Score: 0.258
  15. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther. 2014 Feb; 141(2):140-9.
    View in: PubMed
    Score: 0.234
  16. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011 Feb; 8(2):97-106.
    View in: PubMed
    Score: 0.193
  17. Combinatorial screen with apoptosis pathway targeted agents alrizomadlin, pelcitoclax, and dasminapant in multi-cell type tumor spheroids. SLAS Discov. 2025 Jun; 33:100230.
    View in: PubMed
    Score: 0.130
  18. A phase 1 study of the combination of BH3-mimetic, navitoclax, and mTORC1/2 inhibitor, vistusertib, in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2025 Feb 25; 95(1):37.
    View in: PubMed
    Score: 0.129
  19. Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I). JCO Precis Oncol. 2024 Sep; 8:e2400418.
    View in: PubMed
    Score: 0.125
  20. Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial. Oncologist. 2024 Jul 05; 29(7):638-e952.
    View in: PubMed
    Score: 0.124
  21. Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
    View in: PubMed
    Score: 0.123
  22. Phase I/II Study of Combined BCL-xL and MEK Inhibition with Navitoclax and Trametinib in KRAS or NRAS Mutant Advanced Solid Tumors. Clin Cancer Res. 2024 May 01; 30(9):1739-1749.
    View in: PubMed
    Score: 0.122
  23. The effect of liver dysfunction on the pharmacokinetic disposition of belinostat and its five metabolites in patients with advanced cancers. Cancer Chemother Pharmacol. 2024 Aug; 94(2):157-167.
    View in: PubMed
    Score: 0.121
  24. The NCI-MATCH trial: lessons for precision oncology. Nat Med. 2023 Jun; 29(6):1349-1357.
    View in: PubMed
    Score: 0.115
  25. Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521.
    View in: PubMed
    Score: 0.108
  26. Population Pharmacokinetics of Z-Endoxifen?in Patients With Advanced Solid Tumors. J Clin Pharmacol. 2022 09; 62(9):1121-1131.
    View in: PubMed
    Score: 0.106
  27. Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234.
    View in: PubMed
    Score: 0.106
  28. SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. Cancer Res. 2021 06 01; 81(11):3067-3078.
    View in: PubMed
    Score: 0.099
  29. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst. 2021 01 04; 113(1):27-37.
    View in: PubMed
    Score: 0.097
  30. The emerging landscape of immune checkpoint inhibitor based clinical trials in adults with advanced rare tumors. Hum Vaccin Immunother. 2021 07 03; 17(7):1935-1939.
    View in: PubMed
    Score: 0.097
  31. Molecular Features of Cancers Exhibiting Exceptional Responses to Treatment. Cancer Cell. 2021 01 11; 39(1):38-53.e7.
    View in: PubMed
    Score: 0.096
  32. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH). J Clin Oncol. 2020 11 20; 38(33):3883-3894.
    View in: PubMed
    Score: 0.095
  33. The Molecular Analysis for Therapy Choice (NCI-MATCH) Trial: Lessons for Genomic Trial Design. J Natl Cancer Inst. 2020 10 01; 112(10):1021-1029.
    View in: PubMed
    Score: 0.095
  34. A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors. Invest New Drugs. 2020 06; 38(3):855-865.
    View in: PubMed
    Score: 0.088
  35. Drug delivery of oral anti-cancer fluoropyrimidine agents. Expert Opin Drug Deliv. 2017 12; 14(12):1355-1366.
    View in: PubMed
    Score: 0.075
  36. Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr Probl Cancer. 2017 May - Jun; 41(3):182-193.
    View in: PubMed
    Score: 0.074
  37. Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200.
    View in: PubMed
    Score: 0.074
  38. Precision medicine in oncology. Curr Probl Cancer. 2017 May - Jun; 41(3):163-165.
    View in: PubMed
    Score: 0.074
  39. National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014; 71-6.
    View in: PubMed
    Score: 0.060
  40. A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer. Invest New Drugs. 2014 Apr; 32(2):295-302.
    View in: PubMed
    Score: 0.058
  41. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.057
  42. NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24.
    View in: PubMed
    Score: 0.055
  43. Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res. 2011 Feb 15; 17(4):654-66.
    View in: PubMed
    Score: 0.049
  44. Experimental therapies: Investigator-initiated cancer trials with INDs for approval in Japan. Nat Rev Clin Oncol. 2010 Mar; 7(3):127-8.
    View in: PubMed
    Score: 0.046
  45. Phase II Study of Defactinib (VS6063) in Patients With Tumors With NF2 Loss: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol U. JCO Precis Oncol. 2024 Dec; 8:e2400327.
    View in: PubMed
    Score: 0.032
  46. Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D. JCO Precis Oncol. 2024 Sep; 8:e2400258.
    View in: PubMed
    Score: 0.031
  47. Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G. Oncologist. 2024 Aug 05; 29(8):723-e1093.
    View in: PubMed
    Score: 0.031
  48. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: a phase I study. Biol Blood Marrow Transplant. 2004 Jul; 10(7):473-83.
    View in: PubMed
    Score: 0.031
  49. A Phase II Trial of the WEE1 Inhibitor Adavosertib in SETD2-Altered Advanced Solid Tumor Malignancies (NCI 10170). Cancer Res Commun. 2024 07 01; 4(7):1793-1801.
    View in: PubMed
    Score: 0.031
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.